Central neurocytoma represents an uncommon, benign intraventricular neuroepithelial neoplasm that predominantly affects young adults. Consequently, clinicians frequently encounter therapeutic debates when establishing an optimal strategy for central neurocytoma management. Historically, achieving gross total resection has served as the primary cornerstone of long-term tumor control. However, surgical oncologists still debate the immediate necessity of adjuvant radiotherapy, particularly when histopathology reveals elevated proliferative activity. Furthermore, recent clinical investigations challenge historical paradigms by confirming excellent disease-free intervals after complete surgical excision without added irradiation. Therefore, multidisciplinary teams are re-evaluating whether histological markers necessarily mandate upfront radiation. Ultimately, personalized clinical decision-making helps avoid unnecessary treatment toxicity while preserving neurological function.

Clinical Presentation and Anatomy of Central Neurocytomas

Central neurocytomas typically arise within the lateral ventricles near the foramen of Monro or along the septum pellucidum. Because these lesions slowly expand within the ventricular cavities, patients often remain asymptomatic until obstructive hydrocephalus develops. Consequently, increased intracranial pressure triggers prominent clinical symptoms, including persistent headaches, visual disturbances, and papilledema. In addition, patients may present with episodic nausea, vomiting, or progressive cognitive decline. Notably, the median age at clinical onset ranges between twenty and thirty-four years, frequently affecting otherwise healthy young individuals. Magnetic resonance imaging serves as the essential diagnostic tool for anatomical localization. On neuroimaging, the lesions characteristically display heterogeneous signal intensities, scalloped margins, and intratumoral cystic changes. Furthermore, contrast administration typically produces moderate to intense, patchy enhancement across the ventricular mass. As a result, neurosurgeons can differentiate these lesions from intraventricular ependymomas, subependymomas, or central oligodendrogliomas. Therefore, early recognition through high-resolution neuroimaging remains vital to avoid life-threatening cerebrospinal fluid obstruction. Additionally, advanced sequences like magnetic resonance spectroscopy demonstrate prominent choline peaks with decreased N-acetylaspartate, providing further diagnostic specificity before planned surgical resection.

Surgical Approaches and Achieving Gross Total Resection

Surgical excision remains the definitive primary treatment for intraventricular central neurocytomas. Neurosurgeons primarily select between two well-established operative routes: the anterior transcallosal approach and the transcortical-transventricular approach. Specifically, the transcortical route through the middle frontal gyrus provides excellent visualization of large lesions extending into the third ventricle. In contrast, the interhemispheric transcallosal corridor minimizes cortical disruption while granting direct access to bilateral lateral ventricles. Regardless of the selected corridor, achieving gross total resection represents the primary objective of surgical intervention. Complete surgical removal substantially reduces recurrence rates and frequently cures the patient. Moreover, successful microsurgical clearance restores physiological cerebrospinal fluid dynamics without requiring permanent ventricular shunts. However, operating within the deep ventricular system carries inherent surgical hazards. Surgeons must carefully preserve critical surrounding neurovascular structures, such as the internal cerebral veins, thalamostriate veins, and fornices. Consequently, modern neurosurgical practice relies on stereotactic neuronavigation, neuroendoscopic visualization, and ultrasonic aspiration. Thus, meticulous operative technique achieves complete clearance while preventing postoperative neurological deficits. Furthermore, rigorous postoperative imaging must document the complete disappearance of the mass to confirm true total resection rather than subtotal debulking.

The Role of Ki-67 Proliferation Index in Central Neurocytoma Management

Histopathological evaluation confirms central neurocytoma through typical uniform round cells with perinuclear halos and neuronal markers like synaptophysin. Furthermore, neuropathologists routinely calculate the Ki-67 or MIB-1 proliferation labeling index to assess biological aggressiveness. Historically, pathologists designated tumors exhibiting a Ki-67 index above 2% or 3% as atypical central neurocytomas. Numerous retrospective series suggested that higher proliferative indices correlate with increased local recurrence and decreased progression-free survival. As a result, clinicians historically recommended immediate adjuvant radiation therapy for all tumors displaying elevated Ki-67 levels. However, recent evidence suggests that an elevated proliferation index does not uniformly herald clinical relapse if complete resection is attained. In several modern cohorts, patients with Ki-67 values between 5% and 10% remained recurrence-free for years without adjuvant radiation after gross total resection. Therefore, Ki-67 values should not serve as an isolated criterion for immediate post-surgical irradiation. Instead, surgical completeness provides a robust protective effect that counterbalances intermediate proliferative activity. In addition, close serial neuroimaging offers a dependable safety net to catch rare biological progression early. Ultimately, nuanced central neurocytoma management requires clinicians to integrate histopathological indices with precise postoperative radiological verification.

Adjuvant Radiotherapy: Routine Measure or Tailored Rescue?

The indication for postoperative radiotherapy has generated considerable controversy within neuro-oncology. Historically, many centers administered routine external beam radiotherapy or stereotactic radiosurgery following any subtotal resection or atypical histology. Nevertheless, ionizing radiation directed at deep periventricular structures carries significant long-term risks, especially for young patients. Potential complications include radiation-induced cognitive impairment, endocrine dysfunction, optic pathway injury, and secondary malignant transformation. Consequently, clinicians increasingly favor a watchful surveillance strategy over routine adjuvant radiation following gross total resection. If complete surgical removal is radiographically verified, withholding radiotherapy spares patients from debilitating neurocognitive toxicities. Conversely, adjuvant radiation therapy remains highly valuable when substantial residual tumor persists in surgically inaccessible locations. In such instances, stereotactic radiosurgery or intensity-modulated radiotherapy delivers exceptional local control rates exceeding eighty percent. Furthermore, clinicians reserve salvage radiation as a reliable, highly effective therapy if surveillance scans demonstrate genuine tumor progression. Moreover, modern stereotactic protocols allow precise target conformal delivery, minimizing collateral parenchymal radiation if salvage treatment ever becomes necessary. Thus, adopting a tailored, risk-adapted management pathway avoids premature overtreatment while preserving effective salvage options.

Long-Term Surveillance and Multidisciplinary Practice Recommendations

Long-term clinical and radiological surveillance is imperative for all central neurocytoma patients. Even following verified complete surgical excision, late recurrences can occasionally manifest after five to ten years. Therefore, neuro-oncology protocols mandate baseline brain magnetic resonance imaging within forty-eight hours post-surgery to confirm the extent of resection. Subsequently, clinicians perform surveillance imaging every six to twelve months for the initial five years. After five years of documented stability, annual or biennial scans remain prudent to detect delayed recurrence. In addition, multidisciplinary tumor boards should review each case to weigh histological markers against surgical outcomes. When gross total resection is achieved without residual mass, active observation represents the preferred standard of care. Meanwhile, clinicians closely monitor patients for subtle cognitive changes, endocrine deficits, or visual disturbances. If radiographical progression occurs during follow-up, stereotactic radiosurgery or secondary surgical debulking provides excellent disease control. Consequently, shared decision-making empowers patients and families by clearly explaining surveillance timelines, neurological warning signs, and contingency treatment plans. Ultimately, risk-adapted management ensures optimal survival while safeguarding long-term quality of life.

Frequently Asked Questions

What is the typical clinical presentation of a central neurocytoma?

Central neurocytomas usually affect young adults and present with signs of elevated intracranial pressure caused by obstructive hydrocephalus. Common symptoms include progressive headaches, visual deficits, papilledema, nausea, and unsteady gait. Less frequently, patients develop memory impairment or focal neurological deficits due to ventricular distension and regional tissue compression.

Does an elevated Ki-67 index mandate immediate adjuvant radiotherapy?

An elevated Ki-67 index alone does not automatically necessitate adjuvant radiotherapy if gross total resection is achieved. Recent surgical evidence suggests that complete macroscopic excision provides excellent local control even with moderately high proliferation. Consequently, clinicians recommend watchful radiological surveillance, reserving radiation therapy for cases with residual or progressing tumors.

What is the recommended follow-up protocol after complete surgical resection?

Postoperative surveillance requires an early baseline magnetic resonance imaging scan within forty-eight hours of surgery to confirm complete tumor clearance. Thereafter, clinicians obtain routine contrast-enhanced imaging every six to twelve months for five years. Because late relapses can occasionally arise, annual or biennial imaging should continue for at least ten years.

Disclaimer: This content is for informational and educational purposes only and should not be considered medical advice or relied upon for clinical decision-making. Healthcare professionals must exercise their independent clinical judgment. The views and opinions expressed in this article do not necessarily reflect the official policy or position of any medical association or healthcare institution. Refer to the latest local and national guidelines for clinical practice.

References

1. Corvino S et al. Central neurocytomas: Decision-making process of postoperative treatment. Lesson learned. Neurosurg Rev. 2026 Sep 21. doi: 10.1007/s10143-026-04441-4. PMID: 42764320.
2. Mahavadi AK, Patel PM, Kuchakulla M, Shah AH. Central Neurocytoma Treatment Modalities: A Systematic Review Assessing the Outcomes of Combined Maximal Safe Resection and Radiotherapy with Gross Total Resection. World Neurosurg. 2020;137:e487-e494.
3. Rades D, Fehlauer F. Treatment options for central neurocytoma: excellent results with surgery and postoperative radiotherapy. Int J Radiat Oncol Biol Phys. 2002;53(4):905-911.